NEWS & MEDIA
Read our recent announcements

Press
November 18, 2026
Iambic Presents Preclinical Data for CDK2/4 Inhibitor IAM-C1 and Brain-Penetrant KIF18A Inhibitor IAM217 at 2026 EORTC-NCI-AACR Symposium
Read more

Publication
November 18, 2026
IAM-C1, a Potent and Selective Dual CDK2/CDK4 Inhibitor, Demonstrates Robust Antitumor Activity and a Favorable Preclinical Tolerability Profile
Read more

Publication
November 18, 2026
IAM217: a Novel, Brain-penetrant KIF18A Inhibitor for Targeting Chromosomal Instability in Cancer
Read more

Press
November 16, 2026
Iambic Provides Business Updates and Third Quarter 2026 Financial Results
Read more

Press
November 9, 2026
Iambic to participate in Jefferies Global Healthcare Conference
Read more

Press
October 26, 2026
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
Read more

Publication
Presentation
October 23, 2026
Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers
Read more

Press
October 14, 2026
Iambic Announces Pricing of Initial Public Offering
Read more

Press
October 5, 2026
Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate
Read more
.jpg)
Press
September 21, 2026
Iambic Launches Enchant v3 – Molecular Superintelligence Designed to Advance End-to-End Drug Discovery & Development
Read more












.png)

